BioCentury
ARTICLE | Financial News

Amid Onpattro launch, Alnylam raises $387.5M

January 15, 2019 5:08 AM UTC

Just over five months after gaining its first-ever approval of an RNAi therapy, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) has raised $387.5 million in a follow-on funding intended to build its commercial capabilities.

Alnylam priced 5 million shares at $77.50, an 8% discount to the company's closing price of $84.02 on Monday. The company announced the offering shortly after market close, then priced it hours later on Monday evening. Alnylam shed $3.57 to $80.45 on Tuesday. Barclays is the sole underwriter...

BCIQ Company Profiles

Alnylam Pharmaceuticals Inc.